Clinical Trials on Leiomiomatosis peritoneal diseminada

Total 1771 results

The Netherlands Cancer Institute

Recruiting

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (CisCon)

Fallopian Tube Carcinoma | Peritoneal Cancer | FIGO Stage III Ovarian Cancer

Netherlands
Mural Oncology, Inc
Merck Sharp & Dohme LLC

Recruiting

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Taiwan, Canada, Israel, France, United Kingdom, Germany, Belgium, Czechia, Singapore, Australia, Austria, Italy
Sutro Biopharma, Inc.

Active, not recruiting

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Ovarian Carcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer Stage IV

Netherlands
Syndax Pharmaceuticals
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
Imunon

Completed

Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Universitaire Ziekenhuizen KU Leuven
European Commission

Completed

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (EUDARIO)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Germany, Belgium, Italy, Austria, France
Mayo Clinic

Completed

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Terminated

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Endometrioid Tumor | Malignant Ovarian Serous Tumor

United States
Precision Therapeutics

Terminated

ChemoFx® PRO - A Post-Market Data Collection Study

Cervical Cancer | Uterine Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Peritoneal Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Liz-Anne Lewsley
Ovarian Cancer Action

Recruiting

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (BriTROC-2)

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma | Primary Peritoneal Carcinoma | Carcinosarcoma, Ovarian

United Kingdom
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Patients With Ovarian Cancer

Fallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Australia, Bulgaria, Bosnia and Herzegovina, Georgia, Korea, Republic of, Serbia
Takeda

Completed

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University Hospital, Ghent

Completed

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (OvIP1)

Ovarian Cancer | Primary Peritoneal Cancer

Belgium
Gynecologic Oncology Trial & Investigation Consortium
Japanese Gynecologic Oncology Group

Completed

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

Japan, United States, Hong Kong, Korea, Republic of, New Zealand, Singapore
Roswell Park Cancer Institute
Eisai Inc.

Completed

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Neurotoxicity | Primary Peritoneal Cavity Cancer

United States
Charite University, Berlin, Germany
Kliniken Essen-Mitte

Recruiting

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer (KORE)

Fallopian Tube Cancer | Frailty | Ovary Cancer | Peritoneum Cancer

Germany
Rutgers, The State University of New Jersey

Recruiting

Choices About Genetic Testing And Learning Your Risk With Smart Technology (CATALYST)

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Endometrial Cancer | Pancreas Cancer | Peritoneal Cancer

United States
Hansoh BioMedical R&D Company

Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

China
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (CREATIVE)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Fallopian Tube Carcinoma | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome | Primary Peritoneal Carcinoma

United States
ARCAGY/ GINECO GROUP
AstraZeneca

Completed

Genomic BRCA and Extensive ovArian Cancer Testing (GREAT)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

France
University of Minnesota
United States Department of Defense

Completed

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
North Eastern German Society of Gynaecological...
Clovis Oncology, Inc.; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Active, not recruiting

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Clear Cell Carcinoma

Germany
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
Volastra Therapeutics, Inc.

Recruiting

A Study of Sovilnesib in Subjects With Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary | Chromosomal Instability

United States
pharmaand GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
Mario Negri Institute for Pharmacological Research
North Eastern German Society of Gynaecological Oncology

Active, not recruiting

Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Italy, Germany
Cancer Trials Ireland

Active, not recruiting

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Serous Ovarian Tumor | Endometrioid Carcinoma Ovary

Ireland
AA Secord
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynecologic Neoplasms | Uterine Endometrial Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Breast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene Mutation

United States
Mersana Therapeutics
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Terminated

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer

United States, Australia, Canada
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Active, not recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Extra Renal Origin | Clear Cell Adenocarcinoma

United States
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Advanced Solid Tumor With Evidence of Germline or Somatic BRCA

United States, Israel, Spain, Canada, United Kingdom
Beijing Anzhen Hospital

Completed

Tissue Oxygenation During Treatment of Infant Congenital Heart Defects

Acute Kidney Injury | Hypoxia-Ischemia, Brain | Mesenteric Ischemia

China
CanariaBio Inc.
Raptim Research Pvt. Ltd

Recruiting

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Fallopian Tube Neoplasms | Ovarian Cancer | Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma | Ovarian Neoplasm Epithelial

India
ImmunoGen, Inc.

Recruiting

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
University Health Network, Toronto
GlaxoSmithKline

Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Cancer | High Grade Endometrioid Cancer

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Malignant Neoplasms of Female Genital Organs

United States
Memorial Sloan Kettering Cancer Center
Context Therapeutics Inc.

Active, not recruiting

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Granulosa Cell Ovarian Cancer | Low Grade Serous Ovarian/ Primary Peritoneal Cancer | Endometrioid Endometrial Cancer

United States
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States

Clinical Trials on Leiomiomatosis peritoneal diseminada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations